Rohit Nagaraj

“So, first question is on the CDMO front. So, the 2,000 crore guidance for FY30, in terms of EBITDA margins, would it track the current margins on 1,000 crores Or would there be some kind of a dilution that we're expecting?”

“So the first question is in terms of EO availability for our incremental intoxication capacity. So, how are we placed for that? And what is the latest timeline that is suggested by Reliance in terms of the newer project commissioning from their side?”

“So, first question is, you mentioned in your opening remarks that the team did a remarkable job in terms of sourcing the key raw materials during last quarter. How has been the situation during the current ongoing quarter, and are we placed to, you know, get all the materials comparatively for the quarter?”

“So just carrying on the question on biological, how has been the progress during the current quarter, given that last year base quarter, there was a ban and so no sales were observed.”

“First question in terms of the incremental products that we are commercializing, they are also going into traditional applications of pharma.”